Peroxisome Proliferator-Activated Receptor Agonists: Do They Increase Cardiovascular Risk?

Table 2

The effect of TZDs on CV risk. The table shows a comparison between rosiglitazone and pioglitazone on lipid profile and HbA1c levels in various studies [19–23].

TZDs versus placebo	Pioglitazone	Rosiglitazone
Total cholesterol	Neutral	Raised
LDL	Neutral	Raised
HDL	Raised	Raised
Triglycerides	Reduced	Neutral
HbA1c	↓ 1–1.5%	↓ 1–1.5%